MedCity News February 2, 2025
Investors showed appetite for Metsera’s IPO, as shares of the clinical-stage metabolic medicines biotech popped 47% in their Nasdaq debut. Maze Therapeutics and Beta Bionics also priced IPOs; the three companies raised $636 million combined.
Drugs that activate the GLP-1 receptor transformed the treatment of obesity, but biotech company Metsera contends that limitations keep them from expanding their reach. The weekly injections and gastrointestinal side effects pose challenges for adherence to a chronic therapy. GLP-1 drugs are also engineered peptides, which are expensive to manufacture. Metsera has technologies and drug candidates intended to improve on these limitations. With key clinical trial readouts expected this year, the company took its story to investors through an IPO.
Metsera initially planned to offer...
Today's Sponsors
Today's Sponsor